Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + LM-302 + S-1 vs Tislelizumab + SOX in Claudin 18.2-positive Gastric/GEJ Adenocarcinoma
NCT07569068Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tpx-4589 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Ruijin Hospital. Started Apr 2026; status: recruiting.
02
Drugs
tpx-4589
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07569068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07569068.